Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Samson

Showing results (141-150 of 181) with videos related to

Pageof 19
Sort By:
Joint Bone Spine|May 10, 2026
French recommendations for the use of Imaging in Giant Cell ArteritisOlivier Espitia, Hubert de Boysson, Emmanuel Heron, et al.
Rheumatology (Oxford, England)|March 10, 2020
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Journal of Internal Medicine|November 28, 2023
Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohortKevin Chevalier, Benjamin Thoreau, Marc Michel, et al.
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
Journal of Autoimmunity|September 3, 2015
Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study GroupGonzalo de Luna, Dominique Chauveau, Julien Aniort, et al.
Clinical & Translational Immunology|September 17, 2021
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritisMaxime Samson, Hélène Greigert, Marion Ciudad, et al.
Rheumatology (Oxford, England)|May 25, 2020
Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Autoimmunity Reviews|February 24, 2016
Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patientsOlivier Espitia, Maxime Samson, Thomas Le Gallou, et al.
Plos One|September 16, 2017
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patientsMikael Ebbo, Aurélie Grados, Maxime Samson, et al.
Rheumatology (Oxford, England)|March 20, 2019
Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patientsCécile-Audrey Durel, Arnaud Hot, Ludovic Trefond, et al.
Pageof 19

Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
Joint Bone Spine|May 10, 2026
French recommendations for the use of Imaging in Giant Cell ArteritisOlivier Espitia, Hubert de Boysson, Emmanuel Heron, et al.
Rheumatology (Oxford, England)|March 10, 2020
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Journal of Internal Medicine|November 28, 2023
Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohortKevin Chevalier, Benjamin Thoreau, Marc Michel, et al.
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
Journal of Autoimmunity|September 3, 2015
Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study GroupGonzalo de Luna, Dominique Chauveau, Julien Aniort, et al.
Clinical & Translational Immunology|September 17, 2021
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritisMaxime Samson, Hélène Greigert, Marion Ciudad, et al.
Rheumatology (Oxford, England)|May 25, 2020
Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Autoimmunity Reviews|February 24, 2016
Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patientsOlivier Espitia, Maxime Samson, Thomas Le Gallou, et al.
Plos One|September 16, 2017
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patientsMikael Ebbo, Aurélie Grados, Maxime Samson, et al.
Rheumatology (Oxford, England)|March 20, 2019
Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patientsCécile-Audrey Durel, Arnaud Hot, Ludovic Trefond, et al.
Pageof 19